ARWR Stock Overview
Develops medicines for the treatment of intractable diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Arrowhead Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$23.94 |
52 Week High | US$39.83 |
52 Week Low | US$20.67 |
Beta | 0.94 |
11 Month Change | -15.08% |
3 Month Change | 4.68% |
1 Year Change | -11.82% |
33 Year Change | -64.33% |
5 Year Change | -27.96% |
Change since IPO | -53.96% |
Recent News & Updates
Recent updates
Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Shareholder Returns
ARWR | US Biotechs | US Market | |
---|---|---|---|
7D | 1.4% | 0.4% | 0.6% |
1Y | -11.8% | 14.0% | 22.9% |
Return vs Industry: ARWR underperformed the US Biotechs industry which returned 15.8% over the past year.
Return vs Market: ARWR underperformed the US Market which returned 24.9% over the past year.
Price Volatility
ARWR volatility | |
---|---|
ARWR Average Weekly Movement | 7.5% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARWR has not had significant price volatility in the past 3 months.
Volatility Over Time: ARWR's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 525 | Chris Anzalone | arrowheadpharma.com |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases.
Arrowhead Pharmaceuticals, Inc. Fundamentals Summary
ARWR fundamental statistics | |
---|---|
Market cap | US$3.07b |
Earnings (TTM) | -US$538.64m |
Revenue (TTM) | US$19.65m |
151.5x
P/S Ratio-5.5x
P/E RatioIs ARWR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ARWR income statement (TTM) | |
---|---|
Revenue | US$19.65m |
Cost of Revenue | US$0 |
Gross Profit | US$19.65m |
Other Expenses | US$558.28m |
Earnings | -US$538.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.33 |
Gross Margin | 100.00% |
Net Profit Margin | -2,741.43% |
Debt/Equity Ratio | 99.1% |
How did ARWR perform over the long term?
See historical performance and comparison